BRCA2 and neoplasm: Cell viability analyses showed that NCT-505 and olaparib can synergistically reduce tumor cell viability in OV35 (Fig. 6a) and OV39 (Fig. 6b) HGSOC tumor organoids, which possess BRCA2 and BRCA1 mutation, respectively, as well as positive ALDH1A1 expression.